Canine lymphoma remains one of the most frequently diagnosed cancers in veterinary medicine, yet the path to treatment is often fraught with complex decisions and limited options. Laverdia, containing the active ingredient verdinexor, provides an alternative for veterinarians and pet owners who may be waiting to start multi-agent chemotherapy, dealing with a relapse, or seeking a less aggressive therapeutic approach. According to Dr. Craig A. Clifford, an oncologist at BluePearl, the drug fills a critical void by expanding access to care for dogs that might otherwise go untreated.

Beyond its clinical application, the medication offers logistical flexibility through various dosage sizes tailored to different canine weights. While it serves as an important tool for disease management, the manufacturer emphasizes that it requires strict safety protocols. Because the drug is a potential teratogen, it carries specific risks regarding human contact; owners must wear protective gloves when administering tablets or handling a treated pet's waste. Veterinary teams are advised to monitor patients closely for common side effects, including gastrointestinal issues and shifts in liver enzyme levels, ensuring that the convenience of at-home care is balanced with rigorous medical supervision.